SKL11197

SKL11197 is a small molecule drug developed by SK Biopharmaceuticals for the treatment of neuropathic pain, particularly diabetic peripheral neuropathy. It acts as an inhibitor and modulator of several targets, including 12/15-lipoxygenase (12/15-LOX), arachidonate 12-lipoxygenase (ALOX12), hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, and voltage-dependent calcium channels (VDCCs). The compound has undergone Phase 2 clinical trials to assess its efficacy and safety in patients with painful diabetic peripheral neuropathy. Its mechanism involves inhibition of lipoxygenases involved in inflammatory pathways and modulation of ion channels implicated in neuronal excitability[1][2][3][5].